Efficient T-cell engineering is crucial for the success of CAR T-cell therapy research, but it requires multiple labor-intensive steps, including T-cell isolation, activation, and transduction.
A new CAR T therapy design uses the approved drug venetoclax to temporarily disengage engineered immune cells from tumors.
A new AI tool that models how variations in peptides change T cell receptor binding could help design immunotherapies with fewer off-target effects. Protein complexes that adorn the surface of T cells ...
Amazon S3 on MSN
Scientists supercharge T cells to fight cancer like never before
What if cancer isn’t unstoppable — but the immune system just isn’t fully awake? Scientists at the University of Southampton have discovered a powerful new way to activate cancer-killing T cells. By ...
Explore the evolution of T-cell engagers, from experimental concepts to effective therapies for haematologic malignancies.
A phase one study shows personalised T cell activation induced durable immune responses with manageable toxicity in patients with chronic lymphocytic leukaemia receiving targeted therapy.
Metabolomics-Derived Pathway Scores Outperform Inflammatory Protein Markers-Delivering Risk Prediction Where Proteomics Falls Short ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results